AMENDMENTS TO THE CLAIMS

1. (Currently amended) A compound of the general formula (I),



General formula (I)

wherein

R_0 is hydrogen or a (C_1-C_2)alkyl;

R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are the same or different and are each independently selected from the group consisting of hydrogen, a halogen, a perhaloalkyl group, an amino group, a substituted or unsubstituted linear or branched chain (C_1-C_{12})alkyl, (C_3-C_7)cycloalkyl, (C_1-C_{12})alkoxy, cyclo(C_3-C_7)alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, heterocyclylalkyloxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, diarylamino, aralkylamino, hydroxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, alkylthio, aminocarbonylamino, dialkylaminocarbonylamino, carboxylic acid and derivatives thereof;

R_{13} and R_{14} are the same or different and are each independently selected from the group consisting of hydrogen, a substituted or unsubstituted linear or branched chain (C_1-C_4)alkyl, (C_3-C_7)cycloalkyl, (C_3-C_7)cycloalkenyl, bicycloalkyl, bicycloalkenyl, aryl, and aralkyl ,or R_{13} and R_{14} taken together

with the nitrogen atom to which they are attached, form a substituted or unsubstituted 3, 4, 5, 6 or 7-membered heterocyclic ring, wherein said ring contains from 0 to 3 double bonds and from 0 to 2 heteroatoms; and

n is an integer ranging from 1 to 6, wherein if n is an integer ranging from 3 to 6, the carbon chain is linear or branched,

or a ~~derivative, analog,~~ tautomeric form, stereoisomer, ~~polymorph,~~ or pharmaceutically acceptable salt ~~or solvate~~ thereof.

2. (Currently amended) The compound according to claim 1, which is selected from the group consisting of:

11-(2-N,N-Dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;

2-Chloro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;

2-Chloro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole hydrochloride salt;

2-Chloro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2- ,1-a]indole maleic acid salt;

2-Chloro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole D,L-malic acid salt;

2-Chloro-11-(2-N,N-dimethylamino- ethyl)-6H-isoindolo[2,1-a]indole oxalate salt;

2-Chloro-11-(2-N,N-dimethyl- aminoethyl)-6H-isoindolo[2,1-a]indole citrate salt;

2-Fluoro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;

2-Chloro-11-(2-N,N-diethylaminoethyl)-6H-isoindolo[2,1-a]indole citrate salt;

2-Fluoro-11-(2-N,N-diethylaminoethyl)-6H-isoindolo[2,1-a]indole;

2-Chloro-11-(2-N-cyclopropyl-N-methylaminoethyl)-6H-isoindolo[2,1-a]indole citrate salt;

2-Fluoro-11-(2-N-cyclopropyl-N-methylaminoethyl)-6H-isoindolo[2,1-a]indole;

11-(2-N,N-Dimethylaminoethyl)-2-methyl-6H-isoindolo[2,1-a]indole;

11-(2-N,N-Dimethylaminoethyl)-2-methoxy-6H-isoindolo[2,1-a]indole;

2-Bromo-11-(2-N,N-diethylaminoethyl)-6H-isoindolo[2,1-a]indole;

2-Bromo-11-(2-N-methyl-N-cyclopropylaminoethyl)-6H-isoindolo[2,1-a]indole;

4-Chloro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;

3,4-Dichloro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;

1-Chloro-11-(2-N,N-dimethylaminoethyl)-4methyl-6H-isoindolo[2,1-a]indole;

3-Chloro-11-(2-N,N-dimethylaminoethyl)-4methyl-6H-isoindolo[2,1-a]indole;

3-Chloro-11-[(2-N-methylamino)ethyl]-4-methyl-6H-isoindolo[2,1-a]indole;

3-Chloro-11-[(2-N-methyl-N-acetylamino)ethyl]-4methyl-6H-isoindolo[2,1-a]- indole;

3-Chloro-11-[(2-N-methylamino)ethyl]-2-methoxy-6H-isoindolo[2,1-a]- indole;

3-Chloro-11-[(2-N-methylamino)ethyl]-2-sulfoamido-6H-isoindolo[2,1-a]indole;

3-Iodo-11-[(2-N-methylamino)ethyl]-2-methoxy-6H-isoindolo[2,1-a]indole;

11-(2-N,N-Dimethylaminoethyl)-4-trifluoromethyl-6H-isoindolo[2,1-a]indole;

2,4-Difluoro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;

11-(2-Pyrrolidin-1-ylethyl)-6H-isoindolo[2,1-a]indole;

2-Bromo-11-(2-pyrrolidin-1-ylethyl)-6H-isoindolo[2,1-a]indole;

11-(2-(Piperidin-1-yl)ethyl)-6H-isoindolo[2,1-a]indole;

11-(2-(4-Methylpiperazin-1-yl)ethyl)-6H-isoindolo[2,1-a]indole;

11-(3-(Pyrrolidin-1-yl)-1-hydroxyprop-1-yl)-6H-isoindolo[2,1-a]indole;

2-Bromo-11-(3-(piperidin-1-yl)-1-hydroxyprop-1-yl)-6H-isoindolo[2,1-a]indole;

11-(2-N,N-Dimethylaminoethyl)-4-ethyl-6H-isoindolo[2,1-a]indole;

11-(2-N,N-Dimethylamino-1-hydroxyethyl)-6H-isoindolo[2,1-a]indole;

11-(2-N,N-Dimethylaminoethyl)-4-methoxy-6H-isoindolo[2,1-a]indole;

2-Bromo-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;

4-Bromo-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;

4-Fluoro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;

2-Bromo-11-(2-(4methylpiperazin-1-yl)ethyl)-6H-isoindolo[2,1-a]indole; and

~~or a~~ stereoisomers, N-oxides, ~~polymorph,~~ and pharmaceutically acceptable salts ~~or solvate~~ thereof.

3. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent, excipient or solvent and a therapeutically effective amount of a compound according to claim 1.

4. (Previously presented) The pharmaceutical composition according to claim 3, which is in the form of a tablet, a capsule, a powder, a lozenge, a suppository, a syrup, a solution, a suspension or

an injection, wherein said form is administered in a single dose or in multiple dose units.

5. (Cancelled)

6. (Previously presented) A method of modulating 5-HT and melatonin activity in a patient, comprising administering to said patient a therapeutically effective amount of a compound according to claim 1.

7. (Previously presented) A method of selectively modulating the 5-HT receptors of a patient, comprising administering to said patient a therapeutically effective amount of a compound according to claim 1.

8-11. (Cancelled)

12. (Previously presented) A method of modulating 5-HT receptor function in a patient, comprising administering to said patient a therapeutically effective amount of a compound according to claim 1, wherein the compound is isotopically labeled.

13. (Previously presented) The pharmaceutical composition according to claim 3, further comprising a therapeutically effective amount of a 5-HT re-uptake inhibitor, melatonin, a melatoninergic modulator or a pharmaceutically acceptable salt thereof.

14. (Cancelled)

15. (Currently amended)) A method for the treatment ~~or prophylaxis~~ of anxiety, depression, convulsive disorders, obsessive-compulsive disorders, migraine headache, cognitive memory disorders, Attention Deficient Disorder/Hyperactivity Syndrome, personality disorders, psychosis, paraphrenia, psychotic depression, mania, schizophrenia, schizophreniform disorders, withdrawal from drug abuse, panic attacks, reproduction, glaucoma, sleep disorders or disorders associated with

spinal trauma or head injury in a patient, which comprises administering to said patient in need thereof a therapeutically effective amount of a compound according to claim 1.

16. (Currently amended) A method for the treatment ~~or prophylaxis~~ of mild cognitive impairment, Alzheimer's disease, Parkinsonism or Huntington's chorea in a patient, which comprises administering to said patient in need thereof a therapeutically effective amount of a compound according to claim 1.

17. (Previously presented) A method for the treatment of irritable bowel syndrome or chemotherapy induced emesis in a patient, comprising administering to said patient a therapeutically effective amount of a compound according to claim 1.

18. (Previously presented) A method of reducing in a patient morbidity and mortality associated with excess weight, comprising administering to the patient a therapeutically effective amount of a compound according to claim 1.

19. (Cancelled)